Cargando…
ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis
BACKGROUND: The beta-2 adrenergic receptor (ADRB2) Arg16Gly polymorphism may alter the bronchodilation response to long-acting beta2-agonists, thereby influencing the clinical effectiveness of LABAs plus corticosteroids (ICS) treatment. But the results of individual studies are inconclusive. METHODS...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833872/ https://www.ncbi.nlm.nih.gov/pubmed/29670675 http://dx.doi.org/10.1155/2018/5712805 |
_version_ | 1783303556969791488 |
---|---|
author | Wang, Xi Li, Qian Liu, Ruming He, Jin Wu, Di Wang, Yun Zhang, Jun |
author_facet | Wang, Xi Li, Qian Liu, Ruming He, Jin Wu, Di Wang, Yun Zhang, Jun |
author_sort | Wang, Xi |
collection | PubMed |
description | BACKGROUND: The beta-2 adrenergic receptor (ADRB2) Arg16Gly polymorphism may alter the bronchodilation response to long-acting beta2-agonists, thereby influencing the clinical effectiveness of LABAs plus corticosteroids (ICS) treatment. But the results of individual studies are inconclusive. METHODS: A systematic search was conducted in PubMed, Embase, the Cochrane Database, WHO International Clinical Trials Registry Platform, Chinese National Knowledge Infrastructure, Wanfang, Chinese BioMedical Literature Database, and VIP databases. The meta-analysis was performed with RevMan statistical software (version 5.2), and potential publication bias was estimated by Egger's test using STATA (version 12.0), with p < 0.05 indicating significant publication bias. RESULTS: We found 5 cohort studies with a total of 632 patients and included them in the meta-analysis. There are no significant differences in pulmonary function response between patients with the Arg/Arg and Arg/Gly phenotype (SMD −0.04, 95% CI −0.45 to 0.37; p=0.84). There were also no significant differences in the pulmonary function response between patients with the Arg/Arg and Gly/Gly phenotype (MD −0.03, 95% CI −0.07 to 0.02; p=0.28). CONCLUSIONS: Our systematic review and meta-analysis suggest that ADRB2 Arg16Gly polymorphism is not associated with pulmonary response to asthma treatment with ICS plus LABAs. |
format | Online Article Text |
id | pubmed-5833872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58338722018-04-18 ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis Wang, Xi Li, Qian Liu, Ruming He, Jin Wu, Di Wang, Yun Zhang, Jun Can Respir J Review Article BACKGROUND: The beta-2 adrenergic receptor (ADRB2) Arg16Gly polymorphism may alter the bronchodilation response to long-acting beta2-agonists, thereby influencing the clinical effectiveness of LABAs plus corticosteroids (ICS) treatment. But the results of individual studies are inconclusive. METHODS: A systematic search was conducted in PubMed, Embase, the Cochrane Database, WHO International Clinical Trials Registry Platform, Chinese National Knowledge Infrastructure, Wanfang, Chinese BioMedical Literature Database, and VIP databases. The meta-analysis was performed with RevMan statistical software (version 5.2), and potential publication bias was estimated by Egger's test using STATA (version 12.0), with p < 0.05 indicating significant publication bias. RESULTS: We found 5 cohort studies with a total of 632 patients and included them in the meta-analysis. There are no significant differences in pulmonary function response between patients with the Arg/Arg and Arg/Gly phenotype (SMD −0.04, 95% CI −0.45 to 0.37; p=0.84). There were also no significant differences in the pulmonary function response between patients with the Arg/Arg and Gly/Gly phenotype (MD −0.03, 95% CI −0.07 to 0.02; p=0.28). CONCLUSIONS: Our systematic review and meta-analysis suggest that ADRB2 Arg16Gly polymorphism is not associated with pulmonary response to asthma treatment with ICS plus LABAs. Hindawi 2018-01-21 /pmc/articles/PMC5833872/ /pubmed/29670675 http://dx.doi.org/10.1155/2018/5712805 Text en Copyright © 2018 Xi Wang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Wang, Xi Li, Qian Liu, Ruming He, Jin Wu, Di Wang, Yun Zhang, Jun ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis |
title | ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis |
title_full | ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis |
title_fullStr | ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis |
title_full_unstemmed | ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis |
title_short | ADRB2 Arg16Gly Polymorphism and Pulmonary Function Response of Inhaled Corticosteroids plus Long-Acting Beta Agonists for Asthma Treatment: A Systematic Review and Meta-Analysis |
title_sort | adrb2 arg16gly polymorphism and pulmonary function response of inhaled corticosteroids plus long-acting beta agonists for asthma treatment: a systematic review and meta-analysis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833872/ https://www.ncbi.nlm.nih.gov/pubmed/29670675 http://dx.doi.org/10.1155/2018/5712805 |
work_keys_str_mv | AT wangxi adrb2arg16glypolymorphismandpulmonaryfunctionresponseofinhaledcorticosteroidspluslongactingbetaagonistsforasthmatreatmentasystematicreviewandmetaanalysis AT liqian adrb2arg16glypolymorphismandpulmonaryfunctionresponseofinhaledcorticosteroidspluslongactingbetaagonistsforasthmatreatmentasystematicreviewandmetaanalysis AT liuruming adrb2arg16glypolymorphismandpulmonaryfunctionresponseofinhaledcorticosteroidspluslongactingbetaagonistsforasthmatreatmentasystematicreviewandmetaanalysis AT hejin adrb2arg16glypolymorphismandpulmonaryfunctionresponseofinhaledcorticosteroidspluslongactingbetaagonistsforasthmatreatmentasystematicreviewandmetaanalysis AT wudi adrb2arg16glypolymorphismandpulmonaryfunctionresponseofinhaledcorticosteroidspluslongactingbetaagonistsforasthmatreatmentasystematicreviewandmetaanalysis AT wangyun adrb2arg16glypolymorphismandpulmonaryfunctionresponseofinhaledcorticosteroidspluslongactingbetaagonistsforasthmatreatmentasystematicreviewandmetaanalysis AT zhangjun adrb2arg16glypolymorphismandpulmonaryfunctionresponseofinhaledcorticosteroidspluslongactingbetaagonistsforasthmatreatmentasystematicreviewandmetaanalysis |